drugset / Trial / NCT06527937

Pharmacokinetics Study of DESF in Adults With Oral Allergy Syndrome

NCT06527937 ↗

Phase 2 Completed 36 enrolled Aquestive Therapeutics
RandomizedSequentialOpen-labelTreatment

Summary

A 2-part open-label study to assess the pharmacokinetics (PK) and pharmacodynamics (PD) of epinephrine administered as single and repeat doses of DESF in healthy adults with oral allergy syndrome (OAS). In both parts, subjects undergo an oromucosal allergen challenge prior to administration of DESF according to randomization into two cohorts. In Part 1, there are three treatment periods evaluating single and repeat doses of study drug, DESF after an allergen challenge (Treatment Period 1), intramuscular (IM) injection without allergen challenge (Treatment Period 2), and DESF without allergen challenge (Treatment Period 3). In Part 2, there are two treatment periods evaluating single and repeat doses of study drug, DESF after an allergen challenge (Treatment Period 1) and intramuscular (IM) injection without allergen challenge (Treatment Period 2).

Timeline

Start
2024-07-17
Primary completion
2024-10-10
Completion
2024-10-13

Drugs

EvaluationDrugModalityDoseRoute
Subject DESF Unknown 12 mg Other
Subject Epinephrine Injection Unknown 0.3 mg Intramuscular